U.S. commercial launch in thalassemia underway following December 2025 FDA approvalPre-sNDA meeting with FDA for mitapivat ...

Positioned to increase depth of Vafseo prescribing entering 2026 with access to approximately 275,000 patients First patient dosed in ...

The diagnosis and management of invasive fungal infections in adult patients with hematological malignancies remains a ...

Learn about Hepatitis A, its transmission, symptoms, treatment, and the urgent need for vaccination amidst rising cases in ...

Future Pak becomes exclusive U.S. marketer for Mytesi® and Canalevia®-CA1 Meaningful non-dilutive capital enables Jaguar to ...

These suits represent the next frontier: whether manufacturers of regulated cannabis products may be held liable for injuries ...

PREMATURE birth is a significant public health challenge, not only in Tanzania but also across the globe. It poses major ...

I yet another move that underscores that he MAHA movement is more about politics than public health, RFK Jr. is now ...

Travere Therapeutics, Inc., announced that today the U.S. Food and Drug Administration (FDA) has extended the review timeline of its supplemental New Drug Application (sNDA) for FILSPARI® (sparsentan) ...

Nuvation Bio Inc. , a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced preliminary fourth quarter and full year 2025 net product revenue ...

Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated ...